|29th March 2017
This year, Janssen launched Orello, a service for metastatic prostate cancer patients and their loved ones. Blue Latitude Health supported Janssen in their journey to uncover real patient needs to develop the service with the aim of improving the quality of life for men living with prostate cancer.
From initial research through to final execution, developing a patient service like Orello is a truly multidisciplinary process. Each of our internal capabilities was involved in this project, as were a variety of client stakeholders – a wide breadth of expertise and knowledge contributed to the development of the service.
Customer Experience Consultant Eimear Power talks through the process of developing Orello in collaboration with Janssen.
Empathy is at the heart of service design, particularly when designing a service for patients. Qualitative research was central to this project. As much as possible, we wanted to look at these patients through an ethnographic lens. We wanted to understand how these men thought about their disease, and how it affected their everyday lives. What were their biggest concerns and worries? What was it like to be a partner to someone with prostate cancer? What were the partners’ needs, and how did those relate to patient needs?
One thing that really made this project stand out was the emphasis on the carer and their needs. The carer was not viewed as secondary to the patient, they were considered equally in the design process.
Many markets experience cost constraints within the healthcare system that mean that emotional related support is reluctantly deprioritised, often with the carer not in the frame at all. Therefore, it is invaluable when pharma can bridge this gap in any small way. The service aimed to do this, and the first step was to understand the support needs.
As with many clients, Janssen already had existing research and we were able to bring it all together to get as rich a picture as possible. It’s not always about starting from scratch. There were also company initiatives already in place, and we ensured that we understood their objectives and challenges; our goal was to complement or integrate with them where possible.
Our team had the privilege of spending time with patients and their families in their homes, which was invaluable in enabling the team to build empathy and a deep understanding of patient and carer needs. The insight gained during this research phase was the cornerstone of generating concepts for the service.
From the research, a picture began to come into focus. Some of the key insights the team drew on when developing concepts:
The research we conducted with patients was used to develop patient journeys and personas, this not only allowed the team to understand what the patient was feeling, thinking, and doing at any one phase of their prostate cancer but it was also incredibly useful for facilitating conversations around the commercial objectives of the service.
Unfortunately, you cannot be everything to everyone, so the team needed to identify which patients we could best support, and at what point in the journey we felt it would be of most value. It was decided that the objective of the service would be to support patients and their families who are living with mCRPC by improving their quality of life.
|16th August 2019
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
|26th July 2019
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
|16th July 2019
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.